The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Urea Nitrogen, Blood

Urea Nitrogen, Blood

Urea Nitrogen, Blood is a laboratory test that measures the amount of urea nitrogen in the blood.
Urea is a waste product formed when proteins are broken down in the body.
It is filtered out of the blood by the kidneys and excreted in urine.
The Urea Nitrogen, Blood test can help evaluate kidney function and detect conditions like dehydration, urinary tract blockages, and kidney disease.
This test is commonly used to diagnose and monitor various medical conditions.
PubCompare.ai's AI-driven comparison platform can help optimise your research on Urea Nitrogen, Blood by easily locating protocols from literature, pre-prints, and patents, and using intelligent comparisons to identify the best protocols and products for your needs.
Discover the power of AI-assisted research with PubCompare.ai.

Most cited protocols related to «Urea Nitrogen, Blood»

This investigation was performed in the CPCCRN of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (8 (link)). Detailed methods for the TOPICC data collection have been previously described (6 (link)). There were seven sites, and one was composed of two institutions. In brief, patients from newborn to less than 18 years were randomly selected and stratified by hospital from December 4, 2011, to April 7, 2013. Patients from both general/medical and cardiac/cardiovascular PICUs were included. Moribund patients (vital signs incompatible with life for the first 2 hr after PICU admission) were excluded. Only the first PICU admission during hospitalization was included. The protocol was approved by all participating institutional review boards. Other analyses using this database have been published (6 (link), 7 (link), 9 (link), 10 (link)).
Data included descriptive and demographic information (Table 1). Interventions included both surgery and interventional catheterization. Cardiac arrest included closed chest massage within 24 hours before hospitalization or after hospital admission but before PICU admission. Admission source was classified as emergency department, inpatient unit, postintervention unit, or admission from another institution. Diagnosis was classified by the system of primary dysfunction based on the reason for PICU admission; cardiovascular conditions were classified as congenital or acquired.
The primary outcome in this analysis was hospital survival versus death.
Physiologic status was measured using the PRISM physiologic variables (5 (link)) with a shortened time interval (2 hr before PICU admission to 4 hr after admission for laboratory data and the first 4 hr of PICU care for other physiologic variables). For model building, the PRISM components were separated into cardiovascular (heart rate, systolic blood pressure, and temperature), neurologic (pupillary reactivity and mental status), respiratory (arterial Po2, pH, Pco2, and total bicarbonate), chemical (glucose, potassium, blood urea nitrogen, and creatinine), and hematologic (WBC count, platelet count, prothrombin, and partial thromboplastin time) components, and the total PRISM was also separated into neurologic and non-neurologic categories.
The time interval for assessing PRISM data was modified for cardiac patients under 91 days old because some institutions admit infants to the PICU before a cardiac intervention to “optimize” the clinical status but not for intensive care; in these cases, the postintervention period more accurately reflects intensive care. However, in other infants for whom the cardiac intervention is delayed after PICU admission or the intervention is a therapy required because of failed medical management of the acute condition, the routine PRISM data collection time interval is an appropriate reflection of critical illness. Therefore, we identified infants for whom it would be more appropriate to use data from the 4 hours after the cardiac intervention (postintervention time interval) and those for whom using the admission time interval was more appropriate. We operationalized this decision on the conditions likely to present within the first 90 days, the time period when the vast majority of these conditions present (Table 2).
Statistical analyses used SAS 9.4 (SAS Institute Inc., Cary, NC) for descriptive statistics, model development, and fit assessment and R 3.1.1 (The R Foundation for Statistical Computing, Vienna, Austria; http://www.wu.ac.at/statmath) for evaluation of predictive ability. Patient characteristics were descriptively compared and evaluated across sites using the Kruskal-Wallis test for continuous variables and the Pearson chi-square test for categorical variables. The statistical analysis was under the direction of R.H.
The dataset was randomly divided into a derivation set (75%) for model building and a validation set (25%) stratified by the study site. Univariate mortality odds ratios were computed, and variables with a significance level of less than 0.1 were considered candidate predictors for the final model. As was the case for the previously published trichotomous (death, survival with significant new morbidity, and intact survival) model construction, a nonautomated (examined by biostatistician and clinician at each step) backward stepwise selection approach was used to select factors. Multicategorical factors (e.g., diagnostic categories) had factors combined when appropriate per statistical and clinical criteria. Clinician input was included (and paramount) in this process to ensure that the model fit was relevant and consistent with clinical information. Construction of a clinically relevant, sufficiently predictive model using predictors readily available to the clinician took precedence over inclusion based solely on statistical significance. We were cognizant of the existing trichotomous outcome model and attempted, when statistically justified, to create a compatible two-outcome model that could aid in a smooth transition to using the three-outcome approach.
Final candidate models were evaluated based on 2D receiver operating characteristic (ROC) curves (discrimination) and the Hosmer-Lemeshow goodness of fit (calibration). For the entire dataset, goodness of fit with respect to key subgroups was assessed by examining SMRs for descriptive and diagnostic categories not used in the final model. Only categories with at least 10 outcomes in observed and expected cells were used.
Publication 2016
Activated Partial Thromboplastin Time Arteries Bicarbonates Cardiac Arrest Cardiovascular Diseases Cardiovascular System Catheterization Cells Chest Creatinine Critical Illness Diagnosis Discrimination, Psychology Disease Management Ethics Committees, Research Glucose Heart Hospitalization Infant Infant, Newborn Inpatient Intensive Care Massage Operative Surgical Procedures Patients physiology Platelet Counts, Blood Potassium prisma Prothrombin Rate, Heart Reflex Respiratory Diaphragm Respiratory Rate Signs, Vital Systems, Nervous Systolic Pressure Therapeutics Urea Nitrogen, Blood

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Aspartate Transaminase BBIBP-CorV Bilirubin Blood Glucose Breast Feeding Congenital Abnormality Cough COVID 19 Creatinine D-Alanine Transaminase Diarrhea Dyspnea Ethics Committees Fever Hemoglobin Hypersensitivity Immunoglobulin G Infection Leukocyte Count Mental Disorders Patients Placebos Pregnancy Proteins Rhinorrhea SARS-CoV-2 SARS-CoV-2 inactivated vaccines Seizures Serum Severe acute respiratory syndrome-related coronavirus Sore Throat Urea Nitrogen, Blood Urine Vaccination Vaccines Voluntary Workers
We utilized the Cy/+ rat, a Han:SPRD rat with autosomal dominant polycystic kidney disease (ADPKD) (26 (link)). The male Cy/+ rat develops a persistent azotemia starting at about 10 weeks of age which progresses to uremia by about 40 weeks. The renal pathology has been well characterized with initial cyst development in proximal tubules, followed by interstitial fibrosis (27 (link)). The progressive azotemia is accompanied by the usual manifestations of CKD, including anemia, hypertension, and secondary hyperparathyroidism (26 (link)). The spontaneous genetic mutation (Cy) that leads to cystic kidney disease and progressive CKD encodes for a protein of unknown function (28 (link)). This rat colony at the Indiana University School of Medicine has been maintained through successive breeding of heterozygous Cy/+ rats. This is an autosomal dominant condition, such that at birth, 1/4 of the animals are normal (+/+), 1/2 are heterozygotes (Cy/+), and 1/4 are homozygotes (Cy/Cy). Homozygotes (Cy/Cy) of either sex are easily identified after approximately 10 days of age by abdominal palpation of enlarged kidneys and elevation in blood urea nitrogen (BUN), a finding used to verify parental heterozygosity. Homozygous Cy/Cy rats develop massively enlarged kidneys and severe azotemia, and normally die by 4 weeks of age. Heterozygote male animals develop progressive chronic kidney disease (CKD) with a rise in blood urea nitrogen (BUN) by 10 weeks of age and become markedly uremic by 40-50 weeks. Heterozygote female animals (and castrated males) develop progressive CKD with a rise in BUN not detected until 20 weeks of age, followed by uremia at 80 weeks (18 (link), 27 (link), 29 (link), 30 (link)). For the present study, male heterozygotes were utilized and all procedures reviewed and approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee.
Publication 2008
Abdomen Anemia Animals Azotemia Birth Chronic Kidney Diseases Cyst Females Fibrosis Heterozygote High Blood Pressures Homozygote Hyperparathyroidism, Secondary Institutional Animal Care and Use Committees Kidney Kidney, Cystic Kidney Tubules, Proximal Males Multiple Pterygium Syndrome, Autosomal Dominant Mutation Palpation Parent Pharmaceutical Preparations Polycystic Kidney, Autosomal Dominant Rattus norvegicus Staphylococcal Protein A Urea Nitrogen, Blood Uremia
The primary outcome of our GWAS meta-analysis is log-transformed eGFRcrea. This was used by the studies contributing to the CKDGen meta-analyses and for our UKB association analysis. In UKB, creatinine was measured in serum by enzymatic analysis on a Beckman Coulter AU5800 (UKB data field 30700, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=30700) and GFR was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula53 (link),54 (link). For all studies involved in the CKDGen analysis, creatinine concentrations were measured in serum and GFR was estimated based on the CKD-EPI (for individuals >18 years of age)53 (link),54 (link) or the Schwartz (for individuals <= 18 years of age)55 (link) formula. Details on the study-specific measurements for the CKDGen studies were described previously7 (link). For all studies, eGFRcrea was winsorized at 15 or 200 ml/min/1.73 m2 and winsorized eGFRcrea values were log-transformed using a natural logarithm. Secondary outcomes used for downstream analyses include log-transformed eGFRcys and log-transformed BUN. In UKB, cystatin C was measured based on latex enhanced immunoturbidimetric analysis on a Siemens ADVIA 1800 (UKB data field 30720, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=30720) and blood urea was measured by GLDH, kinetic analysis on a Beckman Coulter AU5800 (UKB data field 30670, http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=30670). Details on the cystatin C and blood urea measurements in CKDGen studies can be found in the previous work7 (link),13 (link). In CKDGen and UKB, eGFRcys was obtained from cystatin C measurements using the formula by Stevens et al.56 (link) or the CKD-EPI formula53 (link),54 (link), respectively. In all studies, eGFRcys was winsorized at 15 or 200 ml/min/1.73 m2 and winsorized eGFRcys values were log-transformed using a natural logarithm. Blood urea measurements in mg/dL were multiplied by 2.8 to obtain BUN values, which were then log-transformed using a natural logarithm.
Full text: Click here
Publication 2021
BLOOD Creatinine Enzymes Genome-Wide Association Study Immunoturbidimetry Kinetics Latex Post-gamma-Globulin Serum Urea Urea Nitrogen, Blood
Mouse body weight was determined at baseline, before each drug administration and every week up to 8 weeks. In addition, mice were also examined daily for evaluation of general health including observation for signs of hair loss, piloerection, general gait weakness, condition of the hind paws and tail skin, and gastrointestinal disorders.
Ear cavity temperature was measured using an infrared thermometer (model IRT303HACCP, National Product, MD) at baseline and after weeks 1, 3, 6, and 8 prior to performing the behavioral tests. Core body temperature was measured using a rectal probe (Thermalert TH-5 and TCAT-1A Controller, Physitemp Instruments, Inc) at baseline and after weeks 1, 3, and 6 in two mice from each drug treatment group after brief anesthesia with isoflurane.
The nephrotoxicity of cisplatin and oxaliplatin was assessed by blood urea nitrogen (BUN) levels in samples collected at the end of the 3-week drug treatment. Based on normal mouse BUN values (8–33 mg/dl according to normal reference laboratory values from Research Animal Resources at the University of Minnesota-; values as reported for normal untreated C57BL/6 mice [64 (link)]), BUN levels > 40 mg/dL were used as an indication of developing nephrotoxicity.
Full text: Click here
Publication 2009
Alopecia Anesthetics Behavior Test Body Temperature Body Weight Brief Treatment Cisplatin Debility Dental Caries Gastrointestinal Diseases Isoflurane Mice, Inbred C57BL Mus Oxaliplatin Pharmaceutical Preparations Piloerection Rectum Skin Tail Thermometers Urea Nitrogen, Blood

Most recents protocols related to «Urea Nitrogen, Blood»

The following covariates were considered in the study: age, sex, race/ethnicity, family poverty income ratio (PIR), education level, marital status, the complication of hypertension, and diabetes mellitus (DM), smoker, drinker, body mass index (BMI), waist circumference, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean energy intake, hemoglobin (Hb), fast glucose (FBG), glycosylated hemoglobin (HbA1c), alanine transaminase (Alt), aspartate aminotransferase (Ast), albumin, total cholesterol (TC), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), uric acid (UA), blood urea nitrogen (BUN), serum creatinine (Scr), and estimated glomerular filtration rate (eGFR). Individuals who have smoked less than 100 cigarettes in their lifetime/smoked less than 100 cigarettes in their lifetime, do not smoke at all at present/smoked more than 100 cigarettes in their lifetime, and smoke some days or every day were defined as never smoke, former smokers, and now smokers, respectively. There are three categories of drinkers: current heavy alcohol consumption were defined as ≥3 drinks per day for females, ≥4 drinks per day for males, or binge drinking [≥4 drinks on same occasion for females, ≥5 drinks on same occasion for males] on 5 or more days per month; current moderate alcohol consumption were defined as ≥2 drinks per day for females, ≥3 drinks per day for males, or binge drinking ≥2 days per month. Those who did not meet the above criteria were classified as current mild alcohol user.21 (link) Hypertension was defined as an average systolic blood pressure more than 140 mmHg/diastolic blood pressure greater than 90 mmHg or self-reported use of antihypertensive medication. DM will be assessed by measures of blood glycohemoglobin, fasting plasma glucose, 2-hour glucose (Oral Glucose Tolerance Test), serum insulin in participants aged 12 years and over. Hb, FBG, HbA1c, Alt, Ast, albumin, TC, TG, HDL-C, UA, BUN, Scr, and eGFR were all determined in the laboratory. More information regarding the variables used is available at https://www.cdc.gov/nchs/nhanes/index.htm.
Publication 2023
Alanine Transaminase Albumins Alcohols Antihypertensive Agents BLOOD Cholesterol Creatinine Diabetes Mellitus Ethnicity Females Glomerular Filtration Rate Glucose Hemoglobin Hemoglobin, Glycosylated High Blood Pressures High Density Lipoprotein Cholesterol Index, Body Mass Insulin Males Oral Glucose Tolerance Test Plasma Pressure, Diastolic Serum Smoke Systolic Pressure Transaminase, Serum Glutamic-Oxaloacetic Triglycerides Urea Nitrogen, Blood Uric Acid Waist Circumference
The toxicity of repeated and high dose of CNPs treatment was assessed by histological and hematological analyses. Briefly, Cy5.5-CNPs (10, 22.5 or 90 mg/kg) were intravenously injected into BALB/c mice with single- or multi-dosage (three times). On day 7 after treatments, major organs (liver, lung, spleen, kidney, brain and heart) were collected from mice, and structural abnormalities in organ tissues were assessed by staining with H&E. In the case of hematological analyses, blood samples were collected from the mice on day 7 and centrifuged at 2200 rpm to obtain plasma. The following factors in blood samples were measured; alanine aminotransferase (ALT), blood urea nitrogen (BUN), alkaline phosphatase (ALP), aspartate Aminotransferase (AST), creatine kinase (CK) and troponin I. The cardiotoxicity by Cy5.5-CNPs was further analyzed after multiple-dosage. The heart tissues were collected from mice after treatment with 10, 22.5 or 90 mg/kg of Cy5.5-CNPs three times. The accumulation of Cy5.5-CNPs in heart tissues was observed using a Leica TCS SP8 confocal laser-scanning microscope. Collagen fiber in heart tissues were stained with Masson's trichrome. Briefly, heart tissues were incubated in Bouin's fixative for 30 min at 56 °C, and the nuclei were co-stained with Weigert's iron hematoxylin. Then, cytoplasm was stained with Biebrich scarlet-acid fuchsin, and then differentiated in phosphomolybdic–phosphotungstic acid. The collagen matrix in heart tissues was stained with aniline blue solution. The collagen in heart tissues were quantitatively analyzed using an Image Pro software, and collagen contents were presented in proportion to the total area of heart tissues.
Full text: Click here
Publication 2023
Aftercare Alkaline Phosphatase aniline blue Aspartate Transaminase Biebrich Scarlet BLOOD Brain Cardiotoxicity Cell Nucleus Collagen Congenital Abnormality Creatine Kinase CY5.5 cyanine dye Cytoplasm D-Alanine Transaminase Fibrosis Fixatives Heart Iron Kidney Liver Lung Mice, Inbred BALB C Microscopy, Confocal Mus Phosphotungstic Acid Plasma Spleen Tissues Troponin I Urea Nitrogen, Blood vascular factor
The data on age, gender, body mass index (BMI), name of the disease at admission, medications, FIM scores, Mann assessment of swallowing ability scores, biochemical findings (serum albumin, C-reactive protein, blood urea nitrogen, estimated glomerular filtration rate, and creatinine) were obtained from medical records.
Full text: Click here
Publication 2023
C Reactive Protein Creatinine Gender Glomerular Filtration Rate Index, Body Mass Pharmaceutical Preparations Serum Albumin Urea Nitrogen, Blood
Participant characteristics were summarized descriptively. Comparisons between patients discharged home, admitted to the medical ward, or admitted directly to the ICU were made with Wilcoxson rank sum and Pearson chi-square tests for continuous and categorical variables, respectively. Impact of timing during the pandemic was assessed as days since data collection started (March 8, 2020).
All tests were 2-sided and a P value < .05 was considered statistically significant. All variables were initially assessed for significance using univariable analysis comparing: Patients discharged home versus admitted to the medical ward and; Patients admitted to the medical ward versus ICU (see Tables S1 and S2, Supplemental Digital Content, http://links.lww.com/MD/I601, which shows the results of univariable analysis). A Multivariable logistic regression was fitted separately comparing: Patients discharged home versus admitted to the medical ward and; Patients admitted to the medical ward versus ICU. We opted for 2 logistic regression models to reflect the distinct clinical decision making processes in the ED (i.e., “discharge home” vs “admit to medical ward,” and “admit to medical ward” vs “admit to ICU”).”
Our key associations of interest were race, ethnicity, ADI, English as a primary language, homelessness, and illicit substance use (opiates, cocaine, methamphetamine); variables also included age, gender, and clinical comorbidities, including body mass index (mg/kg2) and clinical severity. We evaluated disease severity using clinical severity scores (sequential organ failure assessment, Charlson comorbidity index) and laboratory markers found in other risk severity scores,[27 (link),28 ] specifically, C-reactive protein (mg/L), ferritin (ug/L), D-dimer (ng/mL), creatine kinase (U/L), troponin (ng/L), procalcitonin (ng/mL), absolute lymphocyte count (K/mL), and blood urea nitrogen (mg/dL). Timing of admission was calculated as days after the first date of data collection (March 8, 2020). In our regression, we controlled for timing of admission and included the square of timing of admission to evaluate how the effect changed over time. To build our regression models, we first included a priori variables based on clinical understanding (i.e., age, sex, sequential organ failure assessment, C-reactive protein, ferritin, and troponin), and then added variables that were significant on univariable analysis.” Variables were excluded if they showed significant co-linearity (variance inflation factors over 10). We used stepwise, backward selection for our logistic regression model, using a P value of over 0.2 as a cutoff to remove variables. Potential interaction between significant variables was explored.
Additionally, we divided differences in number of admissions in 3 groups to visually evaluate changes in admission over time. Groups were created as general phases of the surge in SARS-CoV-2 admissions in our hospital, representing changes in comfort with diagnosis and clinical management of COVID-19. Changes in admission patterns over time were assessed using the Jonckheere–Terpstra test for trend. All data were analyzed using Stata Statistical Software (Release 16. College Station, TX: StataCorp LLC).
Full text: Click here
Publication 2023
Cocaine COVID 19 C Reactive Protein Creatine Kinase Diagnosis Ethnicity Factor X Ferritin fibrin fragment D Index, Body Mass Lymphocyte Count Methamphetamine Opiate Alkaloids Pandemics Patients Procalcitonin SARS-CoV-2 Substance Use Troponin Urea Nitrogen, Blood
Clinical characteristics including detailed medical history and physical examination were obtained from each patient by experienced cardiologists. All data were stored in the database of our institution. Routine biochemistry including blood urea nitrogen, creatinine, glucose, complete blood count, CK-MB, troponin I, and C-reactive protein (CRP) was measured at admission. The FPA concentration (Boehringer, Mannheim) was measured by sandwich enzyme-linked immunosorbent assay method from centrifuged blood samples. Peak CK-MB and peak troponin-I levels were monitored with blood samples taken at 8-h intervals in the coronary care unit.
Systolic and diastolic arterial pressure, previous history of CAD, hypertension (HT), diabetes mellitus (DM), hyperlipidemia (HL), and smoking status were evaluated [6 (link)]. HT was defined by considering the following parameters: (i) patients who were diagnosed with HT with the international diagnostic code and/or (ii) patients who were taking one or more of the following medications: angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, and diuretics treatments for at least 6 months. DM was diagnosed according to at least one of the following criteria: (1) History of DM and taking any anti-diabetic medication; (2) randomly measured blood glucose value of 200 mg/dL or higher; (3) blood glucose level of 126 mg/dL or above after at least 8 h of fasting; and (4) A1c value of 6.5% or higher. Smoking was defined as a regular smoker if occurred at least one cigarette a day in the past month. Family history presence of CAD was defined as the development of atherosclerotic CVD or death from CVD in a first-degree relative (i.e., parent or sibling) before age 55 for males or 65 for females. The presence of HL was defined according to age and sex-adjusted percentiles from the National Health and Nutrition Examination Survey III data [7 (link)]. The height and weight data of the patients were recorded, and body mass index was calculated according to the weight/height(cm)2 formula.
Publication 2023
Adrenergic beta-Antagonists Angiotensin-Converting Enzyme Inhibitors Angiotensin II Receptor Antagonist Arteries BLOOD Blood Glucose Cardiologists Complete Blood Count C Reactive Protein Creatinine Diabetes Mellitus Diastole Diuretics Enzyme-Linked Immunosorbent Assay Females Glucose High Blood Pressures Hyperlipidemia Index, Body Mass Isoenzyme CPK MB Males Parent Patients Pharmaceutical Preparations Physical Examination Pressure, Diastolic Systole Troponin I Urea Nitrogen, Blood

Top products related to «Urea Nitrogen, Blood»

Sourced in Germany, United States, United Kingdom, Japan, Denmark
The ADVIA 1800 is a clinical chemistry analyzer designed for use in medical laboratories. It is capable of performing a wide range of common clinical chemistry tests on patient samples. The ADVIA 1800 automates the analysis process, providing efficient and accurate results to support patient diagnosis and treatment.
Sourced in United States, Japan, Germany, United Kingdom, China, Italy, Canada
The AU5800 is a chemistry analyzer designed for high-throughput clinical laboratory testing. It features advanced optics and automation to provide reliable and efficient sample processing. The core function of the AU5800 is to perform a variety of clinical chemistry tests, including immunoassays, on patient samples.
Sourced in United States, Canada
The QuantiChrom Urea Assay Kit is a colorimetric assay that measures the urea concentration in biological samples. It provides a simple and accurate method for the quantification of urea.
Sourced in United States
The Biochemistry Panel Plus analyzer discs by Abaxis are designed for clinical laboratory use to perform quantitative analysis of various analytes in biological samples. The discs provide a compact and integrated platform for automated processing and testing.
Sourced in United States, United Kingdom, Germany, China, France, Japan, Canada, Netherlands, Mongolia, Switzerland, Australia
ELISA kits are laboratory tools used to detect and quantify specific proteins or other molecules in a sample. The kits utilize enzyme-linked immunosorbent assay (ELISA) technology to identify the target analyte. ELISA kits provide a standardized and reliable method for sample analysis.
Sourced in Switzerland, Germany, United States, France, Japan, Italy, China, United Kingdom, Sweden
The Cobas 8000 is a modular, automated in-vitro diagnostic system designed for high-throughput clinical chemistry and immunochemistry testing. It is used to perform a wide range of laboratory tests, including those for chemistry, immunoassay, and electrolyte analysis. The Cobas 8000 is capable of processing a large volume of samples efficiently and accurately.
Sourced in United States, Germany, Japan, United Kingdom, Australia
The AU480 is an automated chemistry analyzer from Beckman Coulter designed for routine clinical chemistry testing. It utilizes spectrophotometric technology to perform a variety of assays on biological samples.
Sourced in Switzerland, Germany, United States, Japan
The Cobas Integra 800 is a fully automated, high-throughput clinical chemistry analyzer designed for use in medical laboratories. It is capable of performing a wide range of clinical chemistry tests on a variety of sample types. The Cobas Integra 800 utilizes advanced technology to provide accurate and reliable results, with the ability to handle a high volume of samples efficiently.
Sourced in United States, Canada
The QuantiChrom Creatinine Assay Kit is a colorimetric assay that measures creatinine levels in biological samples. The kit provides a simple, direct, and accurate method for determining creatinine concentrations.
Sourced in United States
The Piccolo point-of-care analyzer is a compact, portable device designed for rapid in-vitro diagnostic testing. It utilizes optical technology to analyze small sample volumes and provide quick results on various clinical chemistry parameters.

More about "Urea Nitrogen, Blood"

Urea nitrogen, also known as blood urea nitrogen (BUN), is a crucial biomarker in clinical diagnostics.
It provides insights into kidney function and can help detect conditions like dehydration, urinary tract blockages, and kidney disease.
The BUN test measures the amount of urea, a waste product formed when proteins are broken down in the body.
Elevated BUN levels can indicate impaired kidney function, as the kidneys are responsible for filtering out and excreting urea through urine.
Conversely, low BUN levels may suggest liver disease or malnutrition.
The BUN test is often used in conjunction with other tests, such as creatinine levels, to assess overall kidney health.
Analyzing BUN levels can be done using a variety of analytical platforms, including the ADVIA 1800, AU5800, and Cobas 8000 analyzers.
The QuantiChrom Urea Assay Kit provides a convenient colorimetric method for quantifying urea in biological samples.
ELISA kits are also available for more specific and sensitive BUN measurements.
In addition to traditional laboratory testing, point-of-care analyzers like the Piccolo can provide rapid BUN results, enabling quicker diagnosis and treatment monitoring.
The Biochemistry Panel Plus analyzer discs on the Cobas Integra 800 and AU480 systems also include BUN as part of a comprehensive metabolic panel.
By understanding the role of BUN and utilizing the latest analytical tools, healthcare professionals can optimize the management of kidney-related conditions and ensure accurate monitoring of patients' health.
PubCompare.ai's AI-driven comparison platform can assist researchers in identifying the most suitable BUN testing protocols and products to meet their specific needs.